SCHEMBL2860707

SCHEMBL2860707

COc1cc(OC)c2c(c1)[nH]c(=O)c1c(N)n(-c3ccc(Oc4ccccc4)cc3C)nc12

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BTK Q06187 8/20 0.42
NTRK1 P04629 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
NTRK2 Q16620 1/20 0.41
PDE5A O76074 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
MGLL Q99685 3/20 0.38
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
FAAH O00519 1/20 0.34
PKM P14618 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2871421 0.92 BTK (0.38) BTKNTRK1IGF1RFGFR1NTRK2
SCHEMBL2861396 0.90 BTK (0.39) BTKNTRK1IGF1RFGFR1NTRK2
SCHEMBL2865010 0.88 MGLL (0.43) BTKNTRK1IGF1RFGFR1NTRK2
SCHEMBL2863158 0.88 ABCG2 (0.43) PDE5AABCG2ALDH1A1KMT2ANR1H4
SCHEMBL2864525 0.86 BTK (0.38) BTKMGLL
SCHEMBL2856187 0.84 ABCG2 (0.38) PDE5AABCG2ALDH1A1KMT2A
SCHEMBL2858480 0.83 BTK (0.41) BTK
SCHEMBL2868603 0.80 MGLL (0.40) BTKNTRK1IGF1RFGFR1NTRK2
SCHEMBL2867684 0.80 LMNA (0.42) BTKKMT2APKMHSD17B10
SCHEMBL2871102 0.80 MMP13 (0.38) PDE5AABCG2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 BTK 272/4885NTRK1 381/4885IGF1R 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.